BG103674A - Polymorphous form of zopolrestatmonohydrate - Google Patents

Polymorphous form of zopolrestatmonohydrate

Info

Publication number
BG103674A
BG103674A BG103674A BG10367499A BG103674A BG 103674 A BG103674 A BG 103674A BG 103674 A BG103674 A BG 103674A BG 10367499 A BG10367499 A BG 10367499A BG 103674 A BG103674 A BG 103674A
Authority
BG
Bulgaria
Prior art keywords
zopolrestatmonohydrate
methods
relates
forms
polymorphous form
Prior art date
Application number
BG103674A
Other languages
Bulgarian (bg)
English (en)
Inventor
John Lambert
Timothy Norris
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103674A publication Critical patent/BG103674A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
BG103674A 1998-08-21 1999-08-20 Polymorphous form of zopolrestatmonohydrate BG103674A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
BG103674A true BG103674A (en) 2000-03-31

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103674A BG103674A (en) 1998-08-21 1999-08-20 Polymorphous form of zopolrestatmonohydrate

Country Status (31)

Country Link
US (1) US6159976A (ru)
EP (1) EP0982306A3 (ru)
JP (1) JP2000072769A (ru)
KR (1) KR20000017411A (ru)
CN (1) CN1245804A (ru)
AP (1) AP9901662A0 (ru)
AU (1) AU4453299A (ru)
BG (1) BG103674A (ru)
BR (1) BR9903873A (ru)
CA (1) CA2280590A1 (ru)
EA (1) EA199900675A3 (ru)
EE (1) EE9900385A (ru)
GT (1) GT199900137A (ru)
HR (1) HRP990259A2 (ru)
HU (1) HUP9902783A3 (ru)
ID (1) ID23307A (ru)
IL (1) IL131419A0 (ru)
IS (1) IS5155A (ru)
MA (1) MA26678A1 (ru)
NO (1) NO994027L (ru)
NZ (1) NZ337363A (ru)
OA (1) OA11150A (ru)
PA (1) PA8480601A1 (ru)
PE (1) PE20000993A1 (ru)
PL (1) PL335016A1 (ru)
SG (1) SG83147A1 (ru)
TN (1) TNSN99159A1 (ru)
TR (1) TR199901996A2 (ru)
UY (1) UY25668A1 (ru)
YU (1) YU39899A (ru)
ZA (1) ZA995297B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3597650T3 (da) 2010-07-16 2022-11-21 Univ Columbia Aldosereduktasehæmmere og anvendelser deraf
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (en) * 2013-02-13 2014-08-21 Mylari Banavara L Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
EP4316603A3 (en) 2016-06-21 2024-04-17 The Trustees of Columbia University in the City of New York 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
EP4417260A2 (en) 2017-07-28 2024-08-21 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
KR20220003529A (ko) 2019-04-01 2022-01-10 어플라이드 테라퓨틱스 인크. 알도스 리덕타제의 억제제
AU2020268368A1 (en) 2019-05-07 2022-01-06 Ucl Business Ltd Treatment and detection of inherited neuropathies and associated disorders
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
AU2021264454A1 (en) 2020-05-01 2022-12-08 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
HUP9902783A3 (en) 2001-01-29
MA26678A1 (fr) 2004-12-20
HU9902783D0 (en) 1999-10-28
AP9901662A0 (en) 1999-09-30
EE9900385A (et) 2000-04-17
AU4453299A (en) 2000-03-09
CN1245804A (zh) 2000-03-01
NO994027D0 (no) 1999-08-20
TR199901996A2 (xx) 2000-03-21
US6159976A (en) 2000-12-12
GT199900137A (es) 2001-02-09
HUP9902783A2 (hu) 2000-12-28
IL131419A0 (en) 2001-01-28
PL335016A1 (en) 2000-02-28
EA199900675A2 (ru) 2000-02-28
NO994027L (no) 2000-02-22
YU39899A (sh) 2002-12-10
EA199900675A3 (ru) 2000-06-26
BR9903873A (pt) 2000-09-19
SG83147A1 (en) 2001-09-18
CA2280590A1 (en) 2000-02-21
NZ337363A (en) 2001-01-26
EP0982306A3 (en) 2000-07-05
TNSN99159A1 (fr) 2005-11-10
ZA995297B (en) 2001-02-19
HRP990259A2 (en) 2000-06-30
IS5155A (is) 2000-02-22
JP2000072769A (ja) 2000-03-07
PE20000993A1 (es) 2000-10-04
OA11150A (en) 2003-04-16
UY25668A1 (es) 2001-08-27
EP0982306A2 (en) 2000-03-01
PA8480601A1 (es) 2000-09-29
KR20000017411A (ko) 2000-03-25
ID23307A (id) 2000-04-05

Similar Documents

Publication Publication Date Title
WO2002014252A3 (en) Compositions containing hypoglycemically active stilbenoids
HK1034909A1 (en) Novel fatty analogues for the treatment of diabetes
WO2002013811A3 (en) Compositions containing hypoglycemically active stilbenoids
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
MA27551A1 (fr) Composition immunogene
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BG103674A (en) Polymorphous form of zopolrestatmonohydrate
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE188869T1 (de) Stabilisiertes sonnenschutzmittel
BR9805626A (pt) Combinação , composição cosmética, uso de pelo menos um poliol e processo para estabilizar a procisteìna em uma composição doméstica.
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR0007989A (pt) Composição para o tratamento de cabelo
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
EP1121932A4 (en) DRUGS FOR EYE DISEASES
WO2004050123A3 (en) Concentrated liquid valdecoxib composition
WO1999048851A3 (en) Processes for preparing intermediates
WO2001051489A3 (en) Methods for lowering uric acid levels
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
EP0393636A3 (en) Liquid crystal composition and liquid crystal display using said composition